<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: Multivitamin preparations are the most common <z:chebi fb="15" ids="50733">dietary supplement</z:chebi>, taken by at least one-third of <z:hpo ids='HP_0000001'>all</z:hpo> US adults </plain></SENT>
<SENT sid="1" pm="."><plain>Observational studies have not provided evidence regarding associations of multivitamin use with total and site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence or mortality </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine whether long-term multivitamin supplementation decreases the risk of total and site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> events among men </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN, SETTING, AND PARTICIPANTS: A large-scale, randomized, double-blind, placebo controlled trial (Physicians" Health Study II) of 14 641 male US physicians initially aged 50 years or older (mean [SD] age, 64.3 [9.2] years), including 1312 men with a history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at randomization, enrolled in a common multivitamin study that began in 1997 with treatment and follow-up through June 1, 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTION: Daily multivitamin or placebo </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: Total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (excluding <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancer</z:e>), with prostate, colorectal, and other site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> among the secondary end points </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During a median (interquartile range) follow-up of 11.2 (10.7-13.3) years, there were 2669 men with confirmed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, including 1373 cases of <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> and 210 cases of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with placebo, men taking a daily multivitamin had a statistically significant reduction in the incidence of total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (multivitamin and placebo groups, 17.0 and 18.3 events, respectively, per 1000 person-years; hazard ratio [HR], 0.92; 95% CI, 0.86-0.998; P=.04) </plain></SENT>
<SENT sid="8" pm="."><plain>There was no significant effect of a daily multivitamin on <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (multivitamin and placebo groups, 9.1 and 9.2 events, respectively, per 1000 person-years; HR, 0.98; 95% CI, 0.88-1.09; P=.76), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (multivitamin and placebo groups, 1.2 and 1.4 events, respectively, per 1000 person-years; HR, 0.89; 95% CI, 0.68-1.17; P=.39), or other site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>There was no significant difference in the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality (multivitamin and placebo groups, 4.9 and 5.6 events, respectively, per 1000 person-years; HR, 0.88; 95% CI, 0.77-1.01; P=.07) </plain></SENT>
<SENT sid="10" pm="."><plain>Daily multivitamin use was associated with a reduction in total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> among 1312 men with a baseline history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (HR, 0.73; 95% CI, 0.56-0.96; P=.02), but this did not differ significantly from that among 13 329 men initially without <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (HR, 0.94; 95% CI, 0.87-1.02; P=.15; P for interaction=.07) </plain></SENT>
<SENT sid="11" pm="."><plain>Conclusion In this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00270647 </plain></SENT>
</text></document>